Timeline of incretin therapeutics: difference between revisions
Diff·revision 4 → 5·04:33, 30 Aug 2024
Difference between revision 4 and revision 5 of Timeline of incretin therapeutics. 4 lines changed; the page grew by 341 bytes.
| Revision 4 — 14:38, 21 Aug 2024 ExenatideEzra (talk) sentence case in headings per PP:MOS 1,845 bytes ±0 | Revision 5 — 04:33, 30 Aug 2024 Chromatokid (talk) correct the dose ladder — the maintenance dose is not the maximum dose 2,186 bytes +341 | ||
|---|---|---|---|
| 9 | Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.{{r|holst2007}} | 9 | Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.{{r|holst2007}} |
| 10 | 10 | ||
| + | 11 | Approval dates are jurisdiction-specific; those given are for the first approval in a major market and may differ elsewhere. See [[Regulatory status by jurisdiction]].{{r|ada2024}} | |
| + | 12 | ||
| 11 | == Physiology == | 13 | == Physiology == |
| 12 | | Period | Event | | 14 | | Period | Event | |
| ⋮ | ⋮ | ||
| 25 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 27 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 26 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 28 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| + | 29 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | |
| 27 | 30 | ||
| 28 | {{DEFAULTSORT:Timeline of incretin therapeutics}} | 31 | {{DEFAULTSORT:Timeline of incretin therapeutics}} |
| 29 | [[Category:Timelines]] | 32 | [[Category:Timelines]] |
| 30 | [[Category:Reference material]] | 33 | [[Category:Reference material]] |
| + | 34 | [[Category:Clinical evidence]] | |
| 31 | 35 |